{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:20:52Z","timestamp":1740144052934,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40257-022-00715-x","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T18:02:47Z","timestamp":1659722567000},"page":"729-737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5068-6803","authenticated-orcid":false,"given":"Julianne M.","family":"Falotico","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6873-3217","authenticated-orcid":false,"given":"Amar D.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asghar","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-4193","authenticated-orcid":false,"given":"Jose W.","family":"Ricardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5913-9304","authenticated-orcid":false,"given":"Shari R.","family":"Lipner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"issue":"1","key":"715_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","volume":"85","author":"DE McMahon","year":"2021","unstructured":"McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46\u201355.","journal-title":"J Am Acad Dermatol"},{"key":"715_CR2","doi-asserted-by":"crossref","unstructured":"Shay DK. Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine\u2014United States, March\u2013April 2021. MMWR Morbidity and mortality weekly report. 2021;70.","DOI":"10.15585\/mmwr.mm7018e2"},{"key":"715_CR3","unstructured":"Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine. 2020."},{"key":"715_CR4","doi-asserted-by":"crossref","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020.","DOI":"10.1056\/NEJMoa2034577"},{"issue":"1","key":"715_CR5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/bjd.20639","volume":"186","author":"A Catal\u00e0","year":"2022","unstructured":"Catal\u00e0 A, Mu\u00f1oz-Santos C, Galv\u00e1n-Casas C, et al. Cutaneous reactions after SARS-COV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol. 2022;186(1):142\u201352.","journal-title":"Br J Dermatol"},{"issue":"36","key":"715_CR6","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","volume":"33","author":"TT Shimabukuro","year":"2015","unstructured":"Shimabukuro TT, Nguyen M, Martin D, et al. Safety monitoring in the vaccine adverse event reporting system (VAERS). Vaccine. 2015;33(36):4398\u2013405.","journal-title":"Vaccine"},{"issue":"37","key":"715_CR7","doi-asserted-by":"publisher","first-page":"5923","DOI":"10.1016\/j.vaccine.2020.07.007","volume":"38","author":"PL Moro","year":"2020","unstructured":"Moro PL, Woo EJ, Marquez P, et al. Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011\u20132019. Vaccine. 2020;38(37):5923\u20136.","journal-title":"Vaccine"},{"issue":"13","key":"715_CR8","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.vaccine.2021.02.052","volume":"39","author":"EJ Woo","year":"2021","unstructured":"Woo EJ, Moro PL. Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: reports to the vaccine adverse event reporting system. Vaccine. 2021;39(13):1812\u20137.","journal-title":"Vaccine"},{"issue":"10","key":"715_CR9","volume":"35","author":"P Krajewski","year":"2021","unstructured":"Krajewski P, Matusiak J. Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine. J Eur Acad Dermatol Venereol. 2021;35(10): e632.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"715_CR10","doi-asserted-by":"crossref","unstructured":"Piccolo V, Russo T, Mazzatenta C, et al. COVID vaccine\u2010induced pustular psoriasis in patients with previous plaque type psoriasis. J Eur Acad Dermatol Venereol. 2022.","DOI":"10.1111\/jdv.17918"},{"key":"715_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdcr.2021.08.035","volume":"17","author":"D Perna","year":"2021","unstructured":"Perna D, Jones J, Schadt CR. Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine. JAAD Case Rep. 2021;17:1\u20133.","journal-title":"JAAD Case Rep."},{"key":"715_CR12","unstructured":"Durmaz I, Turkmen D, Altunisik N, et al. Exacerbations of generalized pustular psoriasis, palmoplantar psoriasis, and psoriasis vulgaris after mRNA COVID\u201019 vaccine: A report of three cases. Dermatologic Therapy.e15331."},{"key":"715_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15110","author":"E Bostan","year":"2021","unstructured":"Bostan E, Elmas L, Yel B, et al. Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID-19 vaccines: a report of two cases. Dermatol Ther. 2021. https:\/\/doi.org\/10.1111\/dth.15110.","journal-title":"Dermatol Ther"},{"key":"715_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17582","author":"E Sotiriou","year":"2021","unstructured":"Sotiriou E, Tsentemeidou A, Bakirtzi K, et al. Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre. J Eur Acad Dermatol Venereol. 2021. https:\/\/doi.org\/10.1111\/jdv.17582.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"715_CR15","first-page":"2768","volume":"8","author":"Y-W Huang","year":"2021","unstructured":"Huang Y-W, Tsai T-F. Exacerbation of psoriasis following COVID-19 vaccination: report from a single center. Front Med. 2021;8:2768.","journal-title":"Front Med"},{"issue":"1","key":"715_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15177","volume":"35","author":"ML Musumeci","year":"2022","unstructured":"Musumeci ML, Caruso G, Trecarichi AC, et al. Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: a real life experience. Dermatol Ther. 2022;35(1): e15177.","journal-title":"Dermatol Ther"},{"key":"715_CR17","doi-asserted-by":"crossref","unstructured":"Pitlick MM, Joshi AY, Gonzalez-Estrada A, et al., editors. Delayed systemic urticarial reactions following mRNA COVID-19 vaccination. Allergy and Asthma Proceedings; 2022: OceanSide Publications, Inc.","DOI":"10.2500\/aap.2022.43.210101"},{"key":"715_CR18","doi-asserted-by":"crossref","unstructured":"Magen E, Yakov A, Green I, et al., editors. Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2. Allergy & Asthma Proceedings; 2022.","DOI":"10.2500\/aap.2022.43.210111"},{"issue":"6","key":"715_CR19","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1016\/j.jaip.2021.03.055","volume":"9","author":"CL Ramos","year":"2021","unstructured":"Ramos CL, Kelso JM. \u201cCOVID Arm\u201d: very delayed large injection site reactions to mRNA COVID-19 vaccines. J Allergy Clin Immunol Pract. 2021;9(6):2480\u20131.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"715_CR20","doi-asserted-by":"crossref","unstructured":"Marcantonio\u2010Santa Cruz O, Vidal\u2010Navarro A, Pesqu\u00e9 D, et al. Pityriasis rosea developing after COVID\u201019 vaccination. J Eur Acad Dermatol Venereol. 2021.","DOI":"10.1111\/jdv.17498"},{"key":"715_CR21","doi-asserted-by":"crossref","unstructured":"Piccolo V, Bassi A, Argenziano G, et al. BNT162b2 mRNA COVID\u201019 vaccine\u2010induced chilblain\u2010like lesions reinforces the hypothesis of their relationship with SARS\u2010CoV\u20102. J Eur Acad Dermatol Venereol. 2021.","DOI":"10.1111\/jdv.17320"},{"issue":"2","key":"715_CR22","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jaad.2020.05.109","volume":"83","author":"EE Freeman","year":"2020","unstructured":"Freeman EE, McMahon DE, Lipoff JB, et al. Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries. J Am Acad Dermatol. 2020;83(2):486\u201392.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"715_CR23","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jaad.2020.06.1016","volume":"83","author":"EE Freeman","year":"2020","unstructured":"Freeman EE, McMahon DE, Lipoff JB, et al. The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries. J Am Acad Dermatol. 2020;83(4):1118\u201329.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"715_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/bjd.19163","volume":"183","author":"C Galv\u00e1n Casas","year":"2020","unstructured":"Galv\u00e1n Casas C, Catala A, Carretero Hern\u00e1ndez G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71\u20137.","journal-title":"Br J Dermatol"},{"issue":"1","key":"715_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jaad.2021.09.002","volume":"86","author":"DE McMahon","year":"2022","unstructured":"McMahon DE, Kovarik CL, Damsky W, et al. Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: a registry-based study. J Am Acad Dermatol. 2022;86(1):113\u201321.","journal-title":"J Am Acad Dermatol"},{"issue":"16","key":"715_CR26","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1001\/jama.2021.16496","volume":"326","author":"EJ Woo","year":"2021","unstructured":"Woo EJ, Mba-Jonas A, Dimova RB, et al. Association of receipt of the Ad26. COV2. S COVID-19 vaccine with presumptive Guillain-Barr\u00e9 syndrome, February-July 2021. JAMA. 2021;326(16):1606\u201313.","journal-title":"JAMA"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00715-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00715-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00715-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T02:20:04Z","timestamp":1662949204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00715-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["715"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00715-x","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"type":"print","value":"1175-0561"},{"type":"electronic","value":"1179-1888"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"assertion":[{"value":"18 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ms Falotico, Mr Desai, Mr Shah, and Dr Ricardo have no conflicts of interest. Dr Lipner has served as a consultant for Ortho Dermatologics, Verrica, and Hoth Therapeutics, BelleTorus Corporation, and Hexima.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publish"}},{"value":"There was no funding for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding sources"}},{"value":"All data generated or analyzed during this study are included in this published article. Further enquiries can be directed to the corresponding author.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"All authors contributed substantially to this manuscript. Study concept and design: SRL. Acquisition of data: JMF, ADD, AS, SRL. Analysis and interpretation of data: JMF, ADD, AS, JWR, SRL. Drafting of the manuscript: JMF. Critical revision of the manuscript for important intellectual content: SRL. Study supervision: SRL.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB approval status"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}